Washington, DC, United States – The White House vaccine chief, Moncef Slaoui states that if the Pfizer vaccine gets approved, first Americans are likely to receive the Pfizer Covid-19 vaccine on December.
On Friday, an application was submitted by Pfizer to the US Food and Drug Administration to get authorization for the emergency use of their Covid-19 vaccine.
While their vaccine is likely to get accepted, Slaoui said that when the authorization is given, they will start giving out the vaccine to first Americans the next day of its approval. Slaoui informed the vaccine is likely to be given approval on the second week of December.
Our plan is to be able to ship vaccines to the immunization sites within 24 hours from the approval, so I would expect maybe on day two after approval, on the 11th or on the 12th of December, hopefully, the first people will be immunized across the United States, across all states, in all the areas where the State Departments of Health will have told us where to deliver the vaccine.
Slaoui told CNN.
Experts have said that they will first focus on vaccinating the highest-priority groups, which are the health care workers, the elderly and people with underlying medical conditions. This is due to the limited amount of vaccine available at first.
Pfizer said that currently they are aiming to manufacture 50 million doses of their vaccine in 2020 and 1.3 billion in the upcoming year. If the company is successful in doing so, the fear of the Covid-19 pandemic will finally come to an end before the year 2021 starts.
Pfizer and their German partner BioNTech recently claimed that the Covid-19 vaccine they have made has proven to be 95% effective. The latest data revealed by these companies showed that their vaccine has overall proven to be 95% effective and 94% effective for the volunteers who were over the age of 65 – the individuals who have a weaker immune system compared to youngsters and are at the most risk from the virus.
This is a huge success for these companies as most of the vaccines that were made has proven to be considerably less effective among older people.
Along with this vaccine, another vaccine from a biotech company named Moderna had also revealed that they had received an effective result from their latest trial.
According to Moderna, the early analysis of their Phase 3 trial suggested its vaccine was 94.5 percent effective. This is the second vaccine released in the US to have such high effectiveness after the vaccine of Pfizer and BioNTech.
